Equine synovitis study highlights tradeoffs of ACS and triamcinolone: full analysis

A new equine study in Animals takes a closer look at two common but very different approaches to managing joint inflammation: intra-articular triamcinolone acetonide, a corticosteroid, and autologous conditioned serum, an orthobiologic made from the horse’s own blood. In an IL-1β-induced synovitis model using six healthy adult horses in a crossover design, investigators found that triamcinolone generally performed better on visible inflammatory signs such as swelling and effusion after the early post-injection phase, while ACS showed advantages in some lameness measures and appeared to reduce PGE2 and cartilage catabolism relative to triamcinolone. (holocron.lib.auburn.edu)

That matters because synovitis is increasingly viewed as an early driver of osteoarthritis progression, not just a source of pain. The Auburn University dissertation that includes this study frames the issue directly: treatment of synovitis may need to do more than relieve lameness and should ideally help reshape the synovial environment in ways that could slow disease progression. ACS has been used by many equine practitioners for that reason, but the evidence base has remained uneven. A 2023 systematic review concluded that most equine ACS studies support its use, while also noting that the literature is weakened by limited controls and inconsistent study design. (holocron.lib.auburn.edu)

In the current study, horses received one of five treatments in sequence: PBS, IL-1β alone, IL-1β plus ACS, IL-1β plus triamcinolone, or ACS alone. The results were not a simple win for either therapy. Triamcinolone produced the lowest swelling scores at 24 and 36 hours and the lowest effusion scores at 36 and 48 hours. But ACS was associated with less marked lameness than triamcinolone at 36 and 72 hours in the IL-1β-challenged joints. On the biochemical side, IL-1β alone increased synovial PGE2 by 1.6-fold versus baseline, while the other treatment groups did not show a significant increase. Meanwhile, glycosaminoglycan concentrations were higher in the IL-1β plus triamcinolone group at 24 and 48 hours, a finding the authors interpret as evidence of greater cartilage catabolism relative to ACS. (holocron.lib.auburn.edu)

One of the more clinically relevant findings is that ACS was not inert. When administered alone, it produced increased heat, swelling, joint effusion, and total nucleated cell count in synovial fluid. The investigators ultimately concluded that ACS may still offer benefits in the setting of synovitis by decreasing PGE2 production and limiting cartilage catabolism compared with intra-articular corticosteroids, but they also emphasized that its short-term inflammatory signature needs to be better understood. They noted, too, that the model produced a relatively mild, short-lived synovitis response, which limits how far the findings can be generalized. (holocron.lib.auburn.edu)

The broader literature helps explain why this comparison is getting attention. Earlier in vitro work from the same research group found that ACS and autologous protein solution showed more favorable anti-inflammatory and chondroprotective effects than triamcinolone in an IL-1β co-culture model. Older experimental work in horses with induced osteoarthritis also found ACS could improve clinical and histologic outcomes. But reviews still describe the equine orthobiologics field as promising rather than settled, with substantial variability in product composition, study methods, and outcome measures. (frontiersin.org)

There’s also a practical reason some clinicians may keep looking beyond steroids. A 2024 study in Animals reported that intra-articular triamcinolone altered ACTH, cortisol, glucose, and insulin in horses, with significant increases in resting insulin that the authors said could predispose horses to laminitis, even though the overall laminitis risk appears low in metabolically normal animals. That doesn’t make ACS a replacement for triamcinolone, but it does strengthen the case for steroid-sparing options in selected patients, especially horses with endocrine risk factors. (pdfs.semanticscholar.org)

Why it matters: For veterinary professionals, this study is a reminder that treatment choice in equine joint disease is increasingly about biology, not just short-term symptom suppression. Triamcinolone still looks strong for reducing visible inflammation quickly. ACS, however, may better preserve aspects of the joint environment that matter for longer-term disease modification. The tradeoff is that ACS may also provoke a measurable synovial response of its own, and the current evidence comes from a very small experimental model rather than field cases with naturally occurring osteoarthritis. In practice, that means case selection, horse metabolic status, discipline demands, withdrawal considerations, and pet parent expectations all remain central to decision-making. (holocron.lib.auburn.edu)

What to watch: Watch for larger controlled trials in clinical equine osteoarthritis, especially studies that compare ACS with corticosteroids on durability, return to performance, biomarker changes, and safety in horses with insulin dysregulation or PPID. (holocron.lib.auburn.edu)